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OverexpressionofZa1-antitrypsin isknownto inducepolymer formation,primethecells forendoplasmicreticu-
lum stress and initiate nuclear factor kappa B (NF-kB) signalling. However, whether endogenous expression in
primary bronchial epithelial cells has similar consequences remains unclear. Moreover, the mechanism of NF-
kB activation has not yet been elucidated. Here, we report excessive NF-kB signalling in resting primary bron-
chial epithelial cells from ZZ patients compared with wild-type (MM) controls, and this appears to be mediated
by mitogen-activated protein/extracellular signal-regulated kinase, EGF receptor and ADAM17 activity.
Moreover, we show that rather than being a response to protein polymers, NF-kB signalling in airway-derived
cells represents a loss of anti-inflammatory signalling by M a1-antitrypsin. Treatment of ZZ primary bronchial
epithelial cells with purified plasma M a1-antitrypsin attenuates this inflammatory response, opening up new
therapeutic options to modulate airway inflammation in the lung.
INTRODUCTION
Alpha1-antitrypsin is a 52-kDa serine protease inhibitor (or
serpin), primarily produced by hepatocytes, but also secreted
locally by lung epithelial cells and alveolar macrophages (1,2).
Its known function is to inhibit a number of serine proteases, in-
cluding neutrophil elastase and proteinase 3, thereby preventing
excessive degradation of the extracellular matrix. It has also
been reported to exhibit anti-inflammatory properties, including
the inhibition of tumor necrosis factora (TNFa) gene expression
(3), inhibitionofadisintegrinandmetalloprotease (ADAM)17ac-
tivity in neutrophils and endothelial cells (4,5) and the regulation
of CD14 expression and cytokine release in monocytes (6,7).
The Z mutation (E342K) of a1-antitrypsin causes subtle mis-
folding of the protein that permits polymer formation and
accumulation within the endoplasmic reticulum (ER) of hepato-
cytes or degradation by the proteasome leading to deficiency of
the secreted protein (8,9). This causes hepatic cirrhosis through
toxic gain-of-function within the liver, most likely due to the re-
tention of polymers, and early-onset lung emphysema, due in
large part to the loss of protease inhibition (10). The discovery
of polymers in broncho-alveolar lavage fluid and pulmonary
tissue (11,12), the pro-inflammatory nature of such extracellular
polymers (11,13) and their identification many years after liver
transplantation (14) led to the proposal that pulmonary pathology
could be induced by polymer-induced toxic gain-of-functionwith
inflammation as an additional mechanism (15).
Secreted proteins are first folded within the ER where quality
control systems ensure that only properly folded proteins exit the
organelle (16). Accumulation of unfolded or misfolded proteins
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within the ER induces ‘ER stress’, thereby activating intracellu-
lar signal transduction pathways, collectively called the
unfolded protein response (UPR) (16). This complex cellular re-
sponse evolved to restore ER homeostasis by reducing the load
of newly synthesized protein while increasing the complement
of molecular chaperones, which enhance ER protein-folding
capacity, and increasing the efficiency ofmisfolded protein deg-
radation (Endoplasmic reticulum-associated degradation,
ERAD) (17,18). We have shown previously that mutant Z a1-
-antitrypsin is degraded predominantly by ERAD (19). Remark-
ably, the accumulation of polymers of Z a1-antitrypsin within
the ER of hepatocytes does not activate the UPR but instead
increases the cell’s sensitivity to ER-stress upon a ‘second hit’
owing to impaired ER luminal protein mobility (20–22).
The transcription factor nuclear factor kappa B (NF-kB) reg-
ulates many genes involved in inflammation and cell death, in-
cluding numerous cytokines and chemokines, e.g. interleukin
(IL)-8 (23). Phosphorylation of NF-kB is classically mediated
through the phosphorylation of inhibitor kappa-B alpha
(IkBa); however, NF-kB can also be activated via mitogen-
activated protein kinase (MAPK) signalling cascades (24,25).
Epidermal growth factor (EGF) and related mitogens such
as heparin-binding EGF (HB-EGF), amphiregulin (AREG)
and transforming growth factor (TGF)-a are synthesized as
membrane-bound proteins that upon cleavage by metallopro-
teases (MPs), includingADAMs, bind to and activate the EGF re-
ceptor (EGFR) [reviewed in (26)]. Transactivation of the EGFR
can also occur via activation ofADAMsbyG-protein-coupled re-
ceptor signalling [reviewed in (27)]. Within the lung, EGFR acti-
vation can induce epithelial cell proliferation by activating
extracellular signal-regulated kinases 1 and 2 (ERK1/2). This is
mediated by Ras activation of c-Raf, causing phosphorylation of
the mitogen-activated protein/extracellular signal-regulated
kinase (MEK), which in turn phosphorylates ERK1/2 (28).
Mutants of members of the serpin superfamily, including a1-
-antitrypsin, have been shown to activateNF-kBsignalling, pos-
tulated to be a response to the formation of protein polymers
within the ER (20,21,29). However, this appears to be independ-
ent of their ability to prime cells for ER stress (29). Whether the
local expression of Z a1-antitrypsin by airway epithelial cells in
vivo leads to the formation of protein polymers and to the activa-
tion of the NF-kB pathway remains unclear. We report here the
detection of NF-kB activation in primary bronchial epithelial cells
isolated from patients homozygous for the Z mutation (ZZ) and
demonstrate this to bemediated by increasedADAM17-dependent
EGFR–MEK–ERK signalling in the absence of either detectable
polymer formation or ER stress response. Instead, the activation
of the EGFR in this setting represents a loss of M a1-antitrypsin
phenotype.
RESULTS
Z a1-antitrypsin activates NF-kB in lung epithelial cells
It is well-recognized that overexpression of Z a1-antitrypsin
activates the NF-kB response leading to pro-inflammatory cyto-
kine release (20,21,30). We therefore asked whether expression
of Z a1-antitrypsin regulated by its endogenous promoter in
airway epithelial cells could also activate this pathway.
Primary bronchial epithelial cells were differentiated into
mucin-producing, ciliated epithelial cell layers (Fig. 1A), and
a multiplex ELISA (Meso Scale Discoveryw, Rockville, MD,
USA) of apical washings (air exposed) and basal (liquid
exposed) conditioned medium for IL-8, IL-6, TNFa, IL-1b,
monocyte chemoattractant protein-1 (MCP-1) and interferon
gamma-induced protein-10 (IP-10) was performed (Fig. 1B).
This revealed that resting ZZ-differentiated primary bronchial
epithelial cells secreted more IL-8 basally when compared
with MM cells (P , 0.01). After combined stimulation with
oncostatin M (OSM), TNFa and IL-1b (OSM-mix), the ZZ
differentiated primary bronchial epithelial cells showed sig-
nificantly higher release of MCP-1 (P, 0.01), IP-10 (P,
0.05) and IL-1b (P , 0.01) compared with MM controls. The
reduced secretion of IL-8 most likely reflects the known inhibi-
tory effect ofOSMon IL-1b-induced IL-8 release (31). Todeter-
mine whether this enhanced release of cytokines was mediated
by increased NF-kB signalling, submerged cultures of patient-
derived ZZ primary bronchial epithelial cells were induced to
express increased levels of a1-antitrypsin by treatment with
OSMandNF-kBactivitywas assayed using a luciferase reporter
system (Fig. 1C) (29). Low levels of basal NF-kB luciferase ac-
tivity were detected in MM primary bronchial epithelial cells,
whereasZZ cells showed significantly higher activity at baseline
(P , 0.05 compared with MM; Fig. 1C). When a1-antitrypsin
production was increased by treatment with OSM, the NF-kB
activity in ZZ primary bronchial epithelial cells increased sig-
nificantly (P, 0.001) and the difference between MM and
ZZ cells increased still further (P, 0.01). Stimulation with
TNFa, a cytokine known to induce NF-kB activation, showed
the same difference between MM and ZZ cells (P , 0.05).
The same effect was seen in Tet-On A549 cells overexpressing
either M or Z a1-antitrypsin (Supplementary Material,
Fig. S1). To test whether the baseline difference inNF-kB activ-
ity was related to the transfection of the reporter constructs, we
measured transcription of the NF-kB-dependent chemokine
IL-8, which confirmed basal levels of inflammatory signalling
were higher in ZZ primary bronchial epithelial cells compared
with controls (P , 0.05; Fig. 1D).
Z a1-antitrypsin does not form detectable polymers nor
causes ER stress in lung epithelial cells
NF-kB activation by mutant serpins has previously been asso-
ciated with the accumulation of protein polymers within the
ER (20–22,29). This accumulation has also been shown to exag-
gerateERstress upon a secondhit (20,22). Toverifywhether this
mechanism was responsible for the enhanced NF-kB signalling
in fully differentiated ZZ primary bronchial epithelial cells, we
first measured total secreted and intracellular a1-antitrypsin.
Resting primary bronchial epithelial cells produced unquantifi-
able amounts of a1-antitrypsin, but after stimulation with
OSM-mix for 48 h, a1-antitrypsin was detectable in both the
apical washes and basal supernatant (Fig. 2A). Similar results
were obtained after exclusion of the current smokers, indicating
that the differences in smoking status of the patients between
MM and ZZ patients from which cells were obtained did not
explain the differences in production of a1-antitrypsin (data
not shown).Using the2C1monoclonal antibody that specifically
detects naturally occurringpolymers ofZa1-antitrypsin (32),we
foundno evidence of polymer formation (Fig. 2A).Accordingly,
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Figure1.Za1-antitrypsin expressionenhancesNF-kBsignalling in lungepithelial cells. (A) Schematicdiagramof culturingprimarybronchial epithelial cells at an air
(apical)–liquid (basal) interface.Oncedifferentiated, epithelium is a pseudo-stratified cell layer composed of ciliated cells, goblet cells and basal cells. (B)Meso scale
discoverywof apically andbasally secreted cytokines and chemokines (IL-8, IL-6,TNFa, IL-1b,MCP-1 and IP-10).Cellswere treatedwith oncostatinM (100 ng/ml;
OSM) and TNFa/IL1b (both 20 ng/ml; OSM-mix) as indicated for 48 h before harvesting apical washes and basal medium (mean, n ¼ 6). (C) NF-kB luciferase
activity of undifferentiated MM and ZZ cells. Submerged cells were cultured for 24 h and then transfected with luciferase reporters for 6 h and left 16 h with
OSMor TNFa (20 ng/ml) as indicated. NF-kB reporter activity is corrected forRenilla (mean, n ¼ 3–4). (D) Basal IL-8mRNAexpression levels of undifferentiated
primarybronchial epithelial cellsmeasuredbyqPCR(mean,n ¼ 4). ∗P, 0.05, ∗∗P , 0.01, ∗∗∗P , 0.001versus—with a two-way repeated-measurementsANOVA
(Bonferroni post hoc).
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we could detect no differences in ER proteinmobility, which we
have previously shown occurs in cells containing ER luminal
polymers of a1-antitrypsin [(22) Supplementary Material,
Fig.S2].Todeterminewhether the absenceofpolymer formation
was a feature of lung epithelial cells, we generated stable trans-
fectedA549 lung carcinomacell lines that conditionally expressed
either M or Z a1-antitrypsin under the control of a Tet-On re-
sponsive promoter. As expected, M a1-antitrypsin-expressing
A549cells secretedfive-timesmorea1-antitrypsin thandidZa1-
-antitrypsin-expressing A549 cells (Fig. 2B). Again, we were
unable to detect protein polymers in either the supernatant or cel-
lular lysates (Fig. 2B). As polymer formation is dependent upon
a1-antitrypsin concentration (8),wecompared the relative levels
of a1-antitrypsin in tissue from an explanted cirrhotic ZZ liver
(Fig. 2C) with those in cultured airway epithelial cells. This
revealed a 100-fold higher level of a1-antitrypsin in hepatic
tissue and significant polymer accumulation (Fig. 2C). While
polymerization of a1-antitrypsin in vitro is highly dependent
upon protein concentration, the concentration dependence of
polymerization within the crowded environment of the ER in
vivo is not known.Therefore, to determine the critical concentra-
tion for the polymerization of Z a1-antitrypsin in living cells,
we induced the expression of Z a1-antitrypsin in Tet-On stable
CHO stable cells (22) and measured both total a1-antitrypsin
and polymer levels (Supplementary Material, Fig. S3A). This
revealed that levels of 300 ng a1-antitrypsin per 1 mg of total
lysate protein are necessary before intracellular polymers can
be detected in these cells (Supplementary Material, Fig. S3A).
To test this finding in lung epithelial-derived cells, we induced
expression of Z a1-antitrypsin in Tet-On A549 cells with doxy-
cycline and augmented the protein level by inhibiting ERAD
with lactacystin, a selectiveproteasome inhibitor. This increased
the concentration of intracellular Z a1-antitrypsin of .300 ng
a1-antitrypsin per 1 mg of total lysate, whereupon polymers
were detected (Supplementary Material, Fig. S3B). It therefore
seems likely that the low levels of a1-antitrypsin produced by
airway epithelia are insufficient to generate detectable polymers.
To define whether Z a1-antitrypsin expressed in epithelial
cells alters the ER stress response, we induced expression of a1-
-antitrypsin in fully differentiated primary bronchial epithelial
cells with OSM-mix in the presence or absence of the ER
stress-inducing toxin tunicamycin. We detected no differences
in the basal or OSM-mix-stimulated levels of spliced X-box
binding protein-1 (XBP1s), CCAAT-enhancer-binding protein
homologous protein (CHOP) and growth arrest and DNA
damage-inducible gene 34 (GADD34) mRNA between MM
andZZprimary bronchial epithelial cells (Fig. 2D).As expected,
tunicamycin increased the level of these transcripts; however,
there was not an exaggerated ER stress response in ZZ epithelial
cells (Fig. 2D). Similarly,wewere unable todetect differences in
ER stress by western blot for the KDEL-positive chaperones,
glucose-regulated protein94 (GRP94) and GRP78, in ZZ and
MM cells (Fig. 2E).
Loss of M a1-antitrypsin leads to increased activation of
ERK, which is dependent on MEK and EGFR
Inorder tounderstand themechanismof inflammatory signalling
in ZZ epithelial cells, we next evaluated activation of theNF-kB
pathway components, inhibitor of nuclear factor kappa-B kinase
subunit beta (IKKb), IkBa and p65. To evaluate MAPK signal-
ling, we also measured JNK, p38 MAPK and ERK1/2. This
revealed a significant difference only in the activation of ERK
(P , 0.05; Fig. 3A and SupplementaryMaterial, Fig. S4). Inter-
estingly, depletion ofa1-antitrypsin by siRNAcaused phosphor-
ylation of ERK inMMprimary bronchial epithelial cells, but did
not alter the phosphorylation of ERK in ZZ cells (Fig. 3A). This
effect was specific for ablation of a1-antitrypsin, because silen-
cing a non-specific serpin, neuroserpin (NS), did not increase
phosphorylation of ERK in MM cells. This suggested that it
was the lack of (M) a1-antitrypsin, rather than the presence of
Z a1-antitrypsin, that might be responsible for the phosphoryl-
ation of ERK in ZZ primary bronchial epithelial cells. To test
this, we treated ZZ primary bronchial epithelial cells with
plasma-purified M a1-antitrypsin and observed a suppression
of ERK phosphorylation (P, 0.05; Fig. 3B). We wished to de-
termine whether this loss of function phenotype reflected a lack
of anti-inflammatory activity in Z a1-antitrypsin or if cells
secreted insufficient Z a1-antitrypsin. As concentration of
plasma-purified Za1-antitrypsin to a degree required for this ex-
periment would result in its polymerization, we instead transi-
ently transfected HeLa cells with either M or Z a1-antitrypsin
or empty vector as control. After transfection, the cells produced
high levels of a1-antitrypsin, with ZZ cells producing 20% of
the amount thatMM cells produced (444 ng/mg a1-antitrypsin in
the total lysateversus1995 ng/mga1-antitrypsin in the total lysate
respectively; Supplementary Material, Fig. S5A). Although 14%
(33 ng/mg total lysate) of the extracellular Z a1-antitrypsin
formed polymers (data not shown), the protein was able to
inhibit phosphorylation of ERK1/2 to a similar degree as M a1-
-antitrypsin (Supplementary Material, Fig. S5B). This result is
consistent with a model in which ZZ primary bronchial epithelial
cells secrete insufficient a1-antitrypsin to inhibit ERK1/2 phos-
phorylation, rather than Z a1-antitrypsin lacking the anti-
inflammatory activity per se.
To determine the mechanism of ERK phosphorylation in ZZ
primary bronchial epithelial cells, we treated cells with U0126,
a specific inhibitor ofMEK, or an anti-EGFRblockingmonoclo-
nal antibody. Both reagents abrogated the phosphorylation of
ERK, indicating that the EGFR–MEK-signalling pathway was
involved and was activated by the ligand-binding site of EGFR
(Fig. 3C). Although under some circumstances, the activation
of ERK1/2 can lead to epithelial cell proliferation, we did not
observe differences in the rate of MM and ZZ cell proliferation
(Supplementary Material, Fig. S6A). Attempts to assess the
effect of ERK1/2 inhibition in each cell type were hampered
by toxicity, but it did not appear that modulation of ERK1/2 ac-
tivation affected proliferation of MM or ZZ cells differentially.
Treatment of ZZ cells with purified M a1-antitrypsin did not
appear to affect the rate of proliferation (Supplementary Mater-
ial, Fig. S6B).
ZZ primary bronchial epithelial cells generate higher levels
of ADAM17-dependent EGFR ligands
We reasoned that this increased EGFR signalling might reflect
increased cleavage of membrane-tethered ligands by MMPs
and/or ADAMs. Therefore, we incubated MM and ZZ primary
bronchial epithelial cells with GM6001, a broad-spectrum
metalloproteinase (MP) inhibitor, or TAPI-2, a broad-spectrum
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Figure2.Polymer formationandan (exaggerated)ERstress responseare not causing the augmentedNF-kBresponse. (A)Totala1-antitrypsin (AAT)anda1-antitrypsin
polymerproductionof fullydifferentiatedprimarybronchial epithelial cells stimulatedwithOSM-mix for48 h.Note lackofpolymer signalwith the2C1antibody (mean,
n ¼ 6). (B) Totala1-antitrypsin anda1-antitrypsin polymer production of the overexpressingTet-OnA549 cells after inducing for 48 hwith doxycycline (dox;mean+
SEM, n ¼ 3). (C) Total a1-antitrypsin levels produced by ZZ lung epithelial cells compared with ZZ liver homogenate (n ¼ 3 from one individual). (D) Quantitative
RT-PCR of fully differentiated primary bronchial epithelial cells treated with OSM-mix for 48 h as indicated. Four hours before harvesting, cells were stimulated
with tunicamycin (Tm; 1 mg/ml). XBP1 splicing, CHOP and GADD34 mRNA levels are displayed normalized to the housekeeping genes RPL13A and ATP5B
(mean, n ¼ 6). (E) Western blot for GRP94 and GRP78 using anti-KDEL antibody. Cells were treated as in D but stimulated for 16 h with tunicamycin (mean, n ¼
6). N.D. not detectable. ∗P, 0.05, ∗∗P, 0.01, ∗∗∗P, 0.001 versus—or 0 with a two-way repeated-measurements ANOVA (Bonferroni post hoc).
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MP inhibitor with enhanced ADAM17 inhibitory activity.
TAPI-2 completely blocked the phosphorylation of ERK1/2 in
ZZ cells (P , 0.001), whereas GM6001 failed to affect phos-
phorylation (Fig. 4A). Furthermore, only treatment with
TAPI-2 reduced secretion of IL-8 from ZZ cells (P , 0.01)
(Fig. 4B). As this suggested the involvement of ADAM17, we
next tested the effect of a specific ADAM17 blocking antibody,
D1(A12) (33). At 200 nM, a concentration known to block the
activity of ADAM17 (34), we observed a substantial decrease
in phosphorylation of ERK1/2 (P, 0.05; Fig. 4C).
Aprevious report suggested thatMa1-antitrypsin can directly
inhibit ADAM17 derived from neutrophils (4), and so we
attempted to reproduce this observation. We first performed an
in vitro ADAM17 activity assay by incubating 1 nM ADAM17
with 0–30 mM purified plasma M a1-antitrypsin but were
unable to detect any inhibition of ADAM17 (Fig. 4D). When
using 10 mM b-mercaptoethanol in PBS or PBS alone, two
potent ADAM17 inhibitors, we were able to inhibit its activity,
confirming the functionality of our assay (Fig. 4D). Moreover,
we were unable to detect the formation of a complex between
ADAM17 and either form of a1-antitrypsin (Fig. 4E). Although
it remains controversial as to whether cytoplasmic phosphoryl-
ation of ADAM17 plays an important regulatory role (35), we
also tested for phosphorylation of ADAM17 in MM and ZZ
cells grown with or without supplementary M a1-antitrypsin
(Supplementary Material, Fig. S7). We detected no differences
between these conditions.
To explore this pathway further, we next measured whether
ZZ primary bronchial epithelial cells generated more EGFR
ligands than controls. We detected significantly higher levels
of mRNA encoding HB-EGF and TGFa in ZZ cells compared
with MM controls (P , 0.05 and P ¼ 0.05; Fig. 5A). When
Figure 3. Increased NF-kB response in ZZ primary bronchial epithelial cells is dependent on the ERK/MEK/EGFR pathway. (A) Representative western blot of the
activation of theMAP kinases ERK1/2, JNK and p38MAPKofwhole cell lysates from undifferentiated primary bronchial epithelial cells knocked-out for AATwith
siRNA. Cells were cultured overnight and transfected for 24 h and left 48 h before harvesting. Neuroserpin (NS) siRNA served as a control. Densitometry of four
independent experiments in duplicate (mean,n ¼ 4). (B) ZZprimary bronchial epithelial cells treated for 24 hwith 1 mg/ml purifiedplasmaMa1-antitrypsin normal-
izedERK1/2 levels.Densitometryof four independent experiments in duplicate (mean,n ¼ 4). (C) ZZprimarybronchial epithelial cells treatedwith 10 mMU0126 (a
specificMEK inhibitor) for 8 h or 2 mg/ml anti-EGFR blocking antibody for 24 h. Densitometry of three independent experiments in duplicate (mean, n ¼ 3). ∗P,
0.05, ∗∗P, 0.01, ∗∗∗P , 0.001 versus—or 0 with a two-way repeated-measurements ANOVA (Bonferroni post hoc).
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Figure4.Ma1-antitrypsinprotectsprimarybronchial epithelial cells against constitutively activatedERK1/2 in anADAM17-dependent fashion. (A)Westernblot for
phosphorylated ERK1/2 of whole cell lysates from primary bronchial epithelial cells treated with 25 mM GM6001 (MP inhibitor) or 25 mM TAPI-2 (MMP and
ADAM17 inhibitor) for 24 h. Densitometry of three independent experiments in duplicate (mean, n ¼ 3). (B) IL-8 secretion in supernatant of primary bronchial epi-
thelial cells treated as in A (mean, n ¼ 3). (C) Treatment with D1(A12), a specificADAM17 blocking antibody, inhibits phosphorylation of ERK1/2 in ZZ cells after
6 h. (–) represents a control IgG. Densitometry of three independent experiments in duplicate (mean, n ¼ 3). (D) ADAM17 (1 nM)was incubatedwith 7.5 or 30 mM
plasma M a1-antitrypsin. ADAM17 activity was assayed against a fluorogenic substrate. b-mercaptoethanol (10 mM) in PBS was used as a positive control for in-
hibition. (–) represents baseline ADAM17 activity against the fluorogenic substrate. (E) Silver stain of a Bis–Tris non-reducing PAGE revealed no binding of
ADAM17 to plasma M a1-antitrypsin incubated in a 1:1 molar ratio for 1 h at 378C. ∗P, 0.05, ∗∗P , 0.01, ∗∗∗P , 0.001 versus—with a two-way repeated-
measurements ANOVA (Bonferroni post hoc).
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the EGFR was blocked using a monoclonal antibody to prevent
ligand binding to its receptor, significantly more released
TGFa and AREG was detected in ZZ cells compared with
MM cells (P , 0.05; Fig. 5B). Consistent with these observa-
tions, when we treated MM primary bronchial epithelial cells
with conditioned medium derived from ZZ cultures, we
observed a significant increase in phosphorylation of ERK1/2
after 1 h (P , 0.01), which returned to baseline after 24 h
(P , 0.001; Fig. 5C).
Taken together, these data indicate that the increased NF-kB
signalling in ZZ primary bronchial epithelial cells is caused by
phosphorylation of ERK1/2. This is due to increased availability
of ADAM17-dependent EGFR ligands leading to activation of
the EGFR and signalling via MEK (Fig. 6). Surprisingly, we
Figure 5. EGFR ligands are enriched in ZZ primary bronchial epithelial cells. (A) Basal expression levels of the EGFR ligands HB-EGF, TGFa and AREG in un-
differentiatedprimarybronchial epithelial cells,measuredbyqPCR.EGFwasnotquantifiable (mean,n ¼ 4). (B) IncreasedTGFa andAREGin thecell supernatant of
ZZ primary bronchial epithelial cells after blockade of the EGFR, quantified by ELISA.HB-EGFwas undetectable (mean, n ¼ 3). (C) Conditionedmedium fromZZ
primary bronchial epithelial cell culture given to MM primary bronchial epithelial cells and vice versa. Phosphorylation of ERK1/2 was measured 1 and 24 h after
media exchange.Densitometry of four independent experiments in duplicate (mean, n ¼ 4). ∗P , 0.05, ∗∗P, 0.01, ∗∗∗P , 0.001versus—with a two-way repeated-
measurements ANOVA (Bonferroni post hoc).
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were unable to detect the formation of polymers of a1-antitrypsin
inZZprimary bronchial epithelial cells orA549 lung adenocarcin-
oma cells overexpressing the protein, which may reflect the low
levelsofa1-antitrypsinexpressionofwhich thesecells arecapable.
DISCUSSION
Formany years, it was thought that an imbalance between prote-
ase and antiprotease activity was solely responsible for the
accelerated onset of emphysema in patients homozygous for the
Z allele of a1-antitrypsin [reviewed in (36)]. However, a1-
-antitrypsinhasbeen found topossess additional roles to its antipro-
tease activity, including a range of anti-inflammatory properties
(3–5), and the Z alleles can increase inflammatory NF-kB signal-
ling when overexpressed pulmonary epithelial cells (20,21,30).
The results of our current study using primary bronchial epithelial
cells inwhicha1-antitrypsin is expressedunder thecontrol of its en-
dogenous promoter confirm and extend these findings. We found
Figure 6. ZZ primary bronchial epithelial cells show an enhanced inflammatory response dependent of the ERK/EGFR/ADAM17 pathway. Impaired expression
of a1-antitrypsin in primary bronchial epithelial cells leads to increased phosphorylation of ERK1/2, which is dependent on MEK, EGFR and ADAM17.
M a1-antitrypsin modulates this inflammatory response via a yet undefined mechanism.
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that at the low levels of a1-antitrypsin expression that occur in
these cells, clinically relevant polymer formation is unlikely to
occur. Sufficient a1-antitrypsin is generated by wild-type cells
to suppress ERK1/2 and NF-kB signalling, but this anti-
inflammatory effect appears to be lost in ZZ epithelia, suggest-
ing a novel mechanism for airway pathology in a1-antitrypsin
deficiency. Surprisingly, while ADAM17 is required to gener-
ate secreted EGFR ligands mediating inflammatory signals in
these ZZ cells, we were unable to detect a direct inhibition of
ADAM17 by M a1-antitrypsin.
Many heterologous overexpression systems have reported the
presence of Z a1-antitrypsin polymers both intracellular and in
conditioned medium (20,21). Unexpectedly, but importantly,
we were unable to detect 2C1-positive polymers in primary
bronchial epithelial cultures.Although the2C1monoclonal anti-
body is highly specific for polymers, it is formally possible that it
is less sensitive than other anti-polymer antibodies, for example,
ATZ11.However, inourhandsbothhave similar avidity towards
Z polymers, but the polyclonal antibody ATZ11 is less specific
for polymers, detecting both Z monomers as well as Z polymers
(32). Even if very low levels of Z a1-antitrypsin polymer are
madewithin bronchial epithelial cells, it is unlikely to affect cel-
lular function as we were unable to detect impaired ER protein
mobility nor altered ER stress responsiveness as we have done
previously for polymer-expressing cells (22).
We were unable to identify all components required for
ERK1/2 activation in ZZ primary bronchial epithelial cells. It
is likely there exists a significant level of redundancy in this
system as we were able to detect multiple EGFR ligands to be
increased in the conditioned medium of ZZ cultures. In our
system, a1-antitrypsin did not directly inhibit ADAM17 as has
been reported for neutrophils (4). Interestingly, it has recently
been speculated that endocytosed a1-antitrypsin may modulate
ADAM17 in endothelial cells (5). If intracellular a1-antitrypsin
can indeedmodulate these pathways,multiple potentialmechan-
isms may explain this effect. ADAM-dependent transactivation
of the EGFR by activation of G-protein-coupled receptors can
also occur [reviewed in (27)]. For example, IL-8 can induce
EGFR phosphorylation in epithelial cells via its receptors
C-X-C chemokine receptor1 (CXCR1) and CXCR2 (28,37),
while binding of a1-antitrypsin to IL-8 has been reported to
prevent activation of CXCR1 (4). Although there are contradict-
ory reports concerning the expression ofCXCR1 andCXCR2on
bronchial epithelial cells (38,39), we found that IL-8 release is
increased in ZZ primary bronchial epithelial cells, which poten-
tially might provide an autocrine inflammatory signal in the
absence of sufficient a1-antitrypsin. Alternatively, C-C chemo-
kine ligand20 (also known asMIP-3a) and its receptor C-C che-
mokine receptor6 have been shown to activate ADAM17
causing transactivation of EGFR (40,41).
Taken together, our experiments have demonstrated that
airway epithelial cells have anti-inflammatory activity owing
to the local synthesis of M a1-antitrypsin from its endogenous
promoter and that this effect is lacking in ZZ homozygous epi-
thelial cells because of a lack of a1-antitrypsin secretion. This
raises the possibility that a1-antitrypsin augmentation may
haveunanticipated effectswithin the airway. It also raises thepo-
tential that targeted anti-EGFR therapy might have anti-
inflammatory effects within the lung.
MATERIALS ANDMETHODS
Reagents and antibodies
OSM (100 ng/ml) was purchased from R&D systems, Minneap-
olis,MN,USA, and TNFa and IL-1b (both 10 ng/ml) fromPepro-
tech, Rocky Hill, NJ, USA. Tunicamycin (1 mg/ml) was bought
from Sigma–Aldrich, St. Louis, MO, USA, U0126 (10 nM) from
Promega,Madison,WI,USA,monoclonal (Ab-3) anti-EGFRanti-
body (2 mg/ml), GM6001 (25 mM) and TAPI-2 (25 mM) all from
Calbiochem, Darmstadt, Germany and D1(A12) (200 nM)
(33). Purified plasma M a1-antitrypsin (1 mg/ml) was derived
as described previously (42). All antibodies for immunoblotting
were purchased fromCell Signaling Technology, Danvers,MA,
USA, except secondary HRP-labelled antibodies (Sigma–
Aldrich) and GRP94 and GRP78 were detected using an anti-
KDEL monoclonal antibody (StressGen).
Cell cultures
Primary bronchial epithelial cells were cultured submerged in a
1:1 mixture of Dulbecco’s modified Eagle’s medium (DMEM)
and bronchial epithelial growth medium (BEGM; Clonectics,
San Diego, CA, USA) with BEGM SingleQuot supplements
and growth factors (Clonectics), 1.5 mg/ml bovine serum
albumin (BSA; Sigma–Aldrich), 1 mM HEPES (Invitrogen,
Life Technologies, Breda, the Netherlands) and 100 U/ml peni-
cillin and 100 mg/ml streptomycin (Sigma–Aldrich), shortened
as full medium, at 378C, 5% CO2 (43). Starvation medium con-
sists of full medium except BSA and the SingleQuot supple-
ments EGF and BPE.
Wecarriedout siRNA-mediatedknockdownofa1-antitrypsin
using a SMARTpool of ONTARGETplusa1-antitrypsin siRNA
(Dharmacon, Lafayette, CO, USA) or SERPIN1 siRNA (Dharma-
con) as a mock control. In general, 10 nM siRNA and 1 ml
RNAiMAX (Invitrogen) were used according to manufacturer’s
descriptions, and a1-antitrypsin expression, measured with qPCR
and ELISA, was knocked down .90% after 72 h by this method
(Supplementary Material, Fig. S8).
Primary bronchial epithelial cells were differentiated as described
previously (44). Briefly, cells were cultured submerged until conflu-
ence on semi-permeable Transwell membranes (Corning Costar,
Cambridge, MA, USA) in B/D medium with addition of retinoic
acid(end-concentration15 ng/ml;Sigma–Aldrich)andsubsequently
cultured air-exposed for 14days to allowmucociliary differentiation.
A549 cells were obtained from American Type Culture Col-
lection (ATCC) and stably transfected with the pTetON vector
(Clontech) to obtain Tet-On A549 cells. ELISA confirmed that
production of endogenous a1-antitrypsin protein was below
the level of detection in these cells (data not shown). These
were stably transfected with pTRE2-hyg plasmid encoding M
or Z a1-antitrypsin as described previously (42). Cells were
maintained in DMEM with 10% (v/v) tetracycline-free foetal
bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin,
400 mg/mlgeneticinand400 mg/mlhygromycinB(selectiveantibio-
tics from Invitrogen) at 378C, 5%CO2. Expression of a1-antitrypsin
was usually induced using 2 mg/ml doxycycline (Sigma–Aldrich)
for 48 h. HeLa cells were obtained from ATCC and transient
transfected with pcDNA3.1 encoding M or Z a1-antitrypsin (or
empty vector) as shown previously (19).
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Patient groups
PiZZ a1-antitrypsin-deficient patients were recruited in the
Leiden University Medical Center (LUMC; Leiden, the Nether-
lands). ZZ primary bronchial epithelial cells were acquired by
bronchial biopsy, with approval from theMedical Ethical Com-
mittee of the LUMC. Briefly, bronchial biopsies were washed
with PBS, divided in 2-mm pieces and placed into a fibronectin/
collagen-coated 24-well plate. Twice daily, the explants were
fed with 20 ml B/D medium until they became adherent
(maximum of three days). Then, primary bronchial epithelial
cellswereexpandedsubmergedwith500 mlB/Dmedium,replaced
triweekly. When cultures reached confulence cells were frozen
down in liquid nitrogen until further use. MM primary bronchial
epithelial cells were obtained from tumour-free resected lung
tissue as described previously (43) and matched to ZZ primary
bronchial epithelial cells according to sex, GOLD-stage (0-III)
and smoking status (non-, ex- or current smoker) (Supplementary
Material, Table S1). In each case, care was taken to ensure that
cellsweresourcedonly fromthe2nd–3rdbranchesof thebronchial
tree in order that results from each were directly comparable.
Measurement of total a1-antitrypsin, polymerized
a1-antitrypsin and cytokine release
Total and polymerized a1-antitrypsin were measured in whole
cell lysate (intracellular) and supernatant (secreted) by ELISA
as described previously (32). Cytokine release of fully differen-
tiated cells was measured using a 4-plex Meso Scale Discovery
kit (IL-6, IL-8,TNFaand IL-1b) and singleplexkits (MCP-1and
IP-10; Meso Scale Discoveryw). EGFR ligands were measured
usingcommercially availableELISAs followingmanufacturer’s
protocol (R&D systems). IL-8 release in supernatant of sub-
merged primary bronchial epithelial cultures was quantified
using an IL-8 ELISA kit (Sanquin, Amsterdam, the Nether-
lands).
Protein mobility assay
Submerged cultured primary bronchial epithelial cells were
grown overnight on coated 35-mm glass-bottom petri dishes
(MatTek Corporation, Ashland, MA, USA) and transiently
transfected with an ER-GFP plasmid (45). Live cells were
imaged on an LSM510 confocal microscope (DuoScan; Carl
Zeiss Inc., Thornwood, NY, USA) at 378C as defined in
Ordonez et al. (22). Briefly, ER-GFP was visualized with an
x63/1.4NAoil objective at 488-nm laser andfluorescence recov-
ery after photobleaching experiments were performed. Fluores-
cence recovery curves were obtained by transforming
fluorescence intensities into a percentage scale in which the pre-
bleach time point represents 100% of fluorescence intensity.
Luciferase activity assays
Transfectionwith luciferase reporter plasmidswas typically per-
formed in 6-well plates with 1 mg of either p(5x)ATF6-luc
(Firefly) or pELAM1-luc (Firefly) and 50 ng of pRL-TK
(Renilla) as a transfection efficacy control (29). Cells were trans-
fected for 6 h with 2 ml Lipofectamine LTX (Invitrogen) in
serum-andantibiotic-freeOptiMEMaccording tomanufacturer’s
instructions and lysed the next day using the recommended proto-
col of the Dual-Luciferase Reporter Assay (Promega).
Western blotting
Cells were lysed in 50 ml buffer H [10 mM HEPES, pH 7.9,
50 mM NaCl, 500 mM sucrose, 0.1 mM EDTA and 0.5%, (v/v)
Triton X-100, 1 mM PMSF, 1× CompleteTM protease inhibitor
cocktail (RocheApplied Science,Mannheim,Germany) supple-
mented with phosphatase inhibitors [10 mM tetrasodium pyro-
phosphate, 17.5 mM b-glycerophosphate and 100 mM NaF;
(46,47)]. Sampleswere run on a 10%SDS–PAGEgel and trans-
ferred onto a nitrocellulosemembrane.After blockingwithPBS/
0.05% Tween-20 (v/v)/5% skim-milk (w/v), the membrane was
incubated with the primary antibody (1:1000) in TBS/0.05%
Tween-20 (v/v)/5% BSA (w/v) overnight at 48C. The HRP-
labelled antibody was incubated for 1 h in blocking buffer and
developed with ECL (ThermoScientific).
Quantitative RT-PCR
Total RNAwas isolated and normalizedmRNA levels were cal-
culated using RPL13A and ATP5B as housekeeping genes (48).
Primers used are described in SupplementaryMaterial, Table S2
(49,50). IQ SYBRGreen supermix (Bio-rad, Herculus, CA,
USA) was used for amplification of the cDNA.
ADAM17 activity and binding assay
ADAM17 activity assay was performed as descried earlier (51).
In brief, 1 nM purified recombinant ADAM17 was incubated
with or without 30–0 mM purified plasma M a1-antitrypsin
and assayed for ADAM17 activity using the fluorogenic sub-
strateMOCAc-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2
(R&D systems). Purified plasma M a1-antitrypsin (0.5 mg) was
incubated for 1 h at 378C in a 1:1molar ratio withADAM17, ran
on a Native Page Bis–Tris (3–12% w/v; Invitrogen) gel and
visualized by Silver stain. Both ADAM17 and purified plasma
M a1-antitrypsin were incubated in 50 mM Tris–HCl (pH 7.4),
100 mM NaCl and 10 mM CaCl.
Statistical analysis
Results from primary bronchial epithelial cells are expressed as
single patients (each dot is the average of one patient in dupli-
cate). Results from Tet-On A549 are shown as mean+SEM.
Data were analysed using two-way repeated-measures analysis
of variance (ANOVA) or Student t-test as appropriate. Differ-
ences with P-values , 0.05 were considered to be statistically
significant.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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